Challenges in Mesenchymal Stromal Cell-based Therapies

Area of Science:

• Regenerative Medicine
• Cell Biology
• Immunology

Background:

• Mesenchymal stromal cells (MSCs) were discovered over 50 years ago and recognized for therapeutic potential despite unknown identity.
• Over 1000 MSC-based clinical trials registered, proving safety but lacking sufficient efficacy data for FDA approval.
• Controversies surrounding MSCs persist due to limited understanding of their in vivo identity and functions.

Purpose of the Study:

• To highlight the need for a deeper understanding of Mesenchymal stromal cells (MSCs) biology.
• To address the limitations in current MSC-based therapies.
• To improve the therapeutic efficacy and clinical establishment of MSCs.

Main Methods:

• Review of existing literature on Mesenchymal stromal cells (MSCs).
• Analysis of clinical trial data and FDA approval requirements.
• Discussion on the knowledge gaps in MSC in vivo identity and function.

Main Results:

• MSC therapeutic effects are not consistently stable long-term.
• Clinical efficacy data remains insufficient for regulatory approval.
• Limited progress in understanding MSCs' in vivo origin and functions.

Conclusions:

• Further investigation into the fundamental biology of Mesenchymal stromal cells (MSCs) is crucial.
• Understanding MSCs' in vivo location and function can enhance therapeutic efficacy.
• Improved biological understanding may facilitate MSCs' establishment as approved cell therapies.